Introduction {#Sec1}
============

Due to the progressive nature of type 2 diabetes mellitus (T2DM), patients usually require treatment intensification to maintain glycemic control, eventually resulting in insulin therapy \[[@CR1]\]. After treatment failure on basal insulin, guidelines recommend intensification with either a glucagon-like peptide-1 receptor agonist (GLP-1RA) or mealtime (bolus) insulin \[[@CR1]\]. Premixed insulin can offer a convenient alternative to basal-bolus therapy, controlling both fasting and postprandial glucose with fewer injections. However, premixed insulin requires resuspension, and insufficient mixing can result in incorrect dosing \[[@CR2]\].

Insulin degludec/insulin aspart (IDegAsp) is the first soluble co-formulation of a basal and a rapid-acting insulin analog in a single injection. The unique properties of insulin degludec (IDeg) enable combination with the rapid-acting insulin, insulin aspart \[[@CR3]\]. IDeg has a long duration of action, with a longer half-life and less within-patient variability versus insulin glargine \[[@CR4], [@CR5]\]. The IDegAsp soluble co-formulation has the additional advantage that it does not require resuspension, eliminating the risk of incomplete mixing, which can lead to hypoglycemia \[[@CR6]\].

The efficacy and safety of IDegAsp was investigated in a phase 3 clinical program (BOOST). A combined analysis of two trials \[[@CR7], [@CR8]\] comparing IDegAsp twice daily (BID) with biphasic insulin aspart (BIAsp 30) BID in insulin-experienced patients with T2DM showed that, at similar levels of glycemic control, IDegAsp resulted in a lower fasting plasma glucose (PG), lower rate of overall and nocturnal hypoglycemia and less weight gain compared with BIAsp 30, all at a lower insulin dose \[[@CR9]\].

To optimize the use of health-care resources, the decision to prescribe a particular product is dependent on clinical and economic evidence. Therefore, it is important that the cost-effectiveness of diabetes interventions is investigated. The cost-effectiveness analyses of diabetes interventions have historically been conducted by estimating the long-term clinical consequences as a function of differences in HbA~1c~. However, according to the US Food and Drug Administration guidance, new insulins should be compared with a standard insulin (and not placebo or a non-insulin agent), aiming to achieve similar glycemic control, thus allowing the comparison of safety end points, such as hypoglycemia, body weight, and insulin dose \[[@CR10], [@CR11]\]. This approach is known as 'treat-to-target'. It follows that there are no differences in long-term risk parameters related to HbA~1c~, and a short-term cost-effectiveness model is more appropriate for an economic evaluation of these secondary end points than a long-term model. Such a model has been used to compare treatment with IDeg versus insulin glargine in patients with type 1 diabetes mellitus (T1DM) and T2DM, from Swedish and UK health-care perspectives \[[@CR12]--[@CR14]\].

The objective of this study was to evaluate the cost-effectiveness of IDegAsp BID compared to BIAsp30 BID in patients with T2DM, from a Danish health-care cost perspective, using a short-term cost-effectiveness model.

Methods {#Sec2}
=======

Model Overview {#Sec3}
--------------

Cost-effectiveness analyses combine the incremental cost of an intervention with the incremental health benefit it produces. A cost-effectiveness analysis of IDegAsp BID compared with BIAsp 30 BID in patients with T2DM was conducted, with the benefits measured in quality-adjusted life years (QALYs), a generic measure of health in terms of quantity and quality of life. The main outcome of the cost-effectiveness analysis was the incremental cost-effectiveness ratio (ICER), which is the most commonly used method by health technology assessment bodies across Europe \[[@CR15]--[@CR17]\].

The cost-effectiveness of IDegAsp was analyzed over a 5-year time horizon, a duration considered sufficient to capture the impact of titration and maintenance of treatment, and a discount rate of 3% for costs and effects was applied, as per the recommendations of the Danish Medicines Agency \[[@CR17]\].

A simple and transparent short-term model was developed in Microsoft Excel 2010 (Fig. [1](#Fig1){ref-type="fig"}). Costs included insulin and the direct costs associated with hypoglycemic events. QALYs were calculated by applying a disutility per hypoglycemic event, per self-measured blood glucose (SMBG) test, and a disutility associated with weight gain.Fig. 1Structure of the cost-effectiveness model. The model captured treatment costs (including insulin, needles, and costs associated with SMBG testing) and costs associated with hypoglycemic events (the resource used to treat the event multiplied by the hypoglycemic event rate) for both IDegAsp and comparator. QALYs were calculated by applying disutilities (reduction in HRQoL) per hypoglycemic event, SMBG test, and BMI gain. *BIAsp 30* biphasic insulin aspart, *BMI* body mass index, *HC* health care, *HRQoL* health-related quality of life, *ICER* incremental cost-effectiveness ratio, *IDegAsp* insulin degludec/insulin aspart, *QALY* quality-adjusted life year, *SMBG* self-measured blood glucose

The cost-effectiveness analysis was based on a cohort approach to mimic the treatment of a patient starting on either IDegAsp BID or BIAsp 30 BID and continuing treatment for 5 years. Data from clinical trials of 26 weeks' duration were used to predict the outcomes over the 5 years. The titration period is up to week 16 and the maintenance period is 16 weeks onward, when patients have usually reached a state of maintenance, with regard to insulin dose and glycemic control. The maintenance period was extended beyond the clinical trial duration, i.e., hypoglycemic rate ratios from the maintenance period were assumed to last for the remaining modeling period. Furthermore, end-of-trial doses and body mass index (BMI) were assumed to last for the remaining modeling period.

Patient Population {#Sec4}
------------------

Data included in this model consisted of a combined analysis of two randomized, open label, treat-to-target, multinational, 26-week trials conducted in insulin-experienced patients with T2DM, both comparing IDegAsp BID with BIAsp 30 BID \[[@CR9]\]. The trials were conducted in accordance with ethical guidelines \[[@CR7], [@CR8]\], and this study did not involve any new studies of human or animal subjects performed by any of the authors. The global trial (Intensify Premix 1; ClinicalTrials.gov identifier: NCT01009580) included patients from ten countries (including four European countries: Denmark, Finland, Poland, and Sweden) randomized 1:1 to IDegAsp or BIAsp 30, with T2DM for ≥6 months, ≥18 years of age, HbA~1c~ of 7.0--10.0%, and BMI ≤40 kg/m^2^ who were previously treated with premixed insulin ± oral anti-diabetic drugs (OADs) for ≥3 months \[[@CR7]\]. The second trial (Intensify All; ClinicalTrials.gov identifier: NCT01059812) was a pan-Asian study involving patients from five countries randomized 2:1 to IDegAsp or BIAsp 30, with T2DM for ≥6 months, ≥18 years of age (≥20 years for Japan and Taiwan), HbA~1c~ of 7.0--10.0%, and BMI ≤35 kg/m^2^, who were previously treated with basal, premixed, or self-mixed insulin ± metformin for ≥3 months \[[@CR8]\]. The trial designs were similar, and the patient characteristics are summarized in the primary publications \[[@CR7], [@CR8]\]. In total, 868 patients were included (IDegAsp *n* = 504; BIAsp 30 *n* = 364). Insulin was titrated weekly to a pre-meal SMBG target of 4.0--5.0 mmol/L. Patients with significant concomitant illness \[e.g., history of cardiovascular disease (heart failure: New York Heart Association class III or IV, unstable angina pectoris, or a myocardial infarction) within 6 months preceding the trial and uncontrolled severe hypertension (systolic blood pressure ≥180 mmHg or sitting diastolic blood pressure ≥100 mmHg)\] and those with recurrent severe hypoglycemia or hypoglycemic unawareness were excluded.

Data Used in the Model {#Sec5}
----------------------

### Clinical Data {#Sec6}

#### Insulin Dose {#Sec7}

Daily insulin dose in units (U) was captured during the clinical trials. In this combined analysis, the BIAsp 30 dose was 45.7 U/day at baseline, 81.8 U/day at the end of titration, and 86.2 U/day at the end of the trial (Table [1](#Tab1){ref-type="table"}a). The dose ratios (IDegAsp/IAsp 30) were 0.84 at both the end of titration and end of trial in the combined analysis and assumed to be 1 at baseline (Table [1](#Tab1){ref-type="table"}a). The BIAsp 30 dose and the IDegAsp/BIAsp 30 dose ratio were applied to estimate the IDegAsp dose (Table [1](#Tab1){ref-type="table"}a) to allow for adjustment of the covariates treatment, trial, anti-diabetic therapy at screening, sex, age, region, and baseline insulin dose.Table 1Clinical dataa. Insulin doseBaselineEnd of titrationEnd of trialBIAsp30 group (units/day)^a^45.781.886.2Dose ratio (IDegAsp/BIAsp 30)1.00^b^0.84\*^c^0.84\*^c^IDegAsp group (units/day)45.768.772.4b. HypoglycemiaNon-severe hypoglycemiaSevere hypoglycemiaBaseline hypoglycemia rate (BIAsp 30)^d^10.20.7DaytimeNocturnal--Daytime/nocturnal split^e^82.9%17.1%Total events per patient per year for BIAsp 308.461.740.7Titration IDegAsp/BIAsp 30 hypoglycemic event rate ratio^f^NS (1.00)0.46\*NS (1.00) Calculated IDegAsp hypoglycemic event rate8.460.800.7Maintenance IDegAsp/BIAsp 30 hypoglycemic event rate ratio^f^0.76\*0.39\*0.16\* Calculated IDegAsp hypoglycemic event rate6.430.680.11c. Body mass indexEnd of titrationEnd of trialBIAsp 30 group (change from baseline, BMI points)^g^0.50.7IDegAsp−BIAsp 30 (treatment difference)^g^NS--0.19\*IDegAsp group (change from baseline, BMI points)^h^0.50.51*BIAsp 30* biphasic insulin aspart, *BID* twice daily, *BMI* body mass index, *IDegAsp* insulin degludec/insulin aspart, *NS* non-significant, *T2DM* type 2 diabetes mellitus, *UKHSG* UK Hypoglycaemia Study Group\* Significant, *P* \< 0.05^a^Derived from a combined analysis of insulin dose (a post hoc analysis)^b^Dose ratio assumed equal at baseline^c^Insulin dose ratios derived from the combined analysis \[[@CR9]\]^d^Baseline hypoglycemia rates are mean rates for patients with T2DM using insulin for more than 5 years included in UKHSG \[[@CR18]\]^e^Proportion of daytime/nocturnal events for BIAsp 30 taken from the combined analysis (a post hoc analysis)^f^Event rate ratios were derived from the combined analysis \[[@CR9]\], and the relative rates were adjusted for treatment, trial, anti-diabetic therapy at screening, sex, and region as fixed factors and age as a continuous covariate. In case of non-significant results, a relative rate of one was used in the calculation^g^Derived from a combined analysis of BMI (a post hoc analysis)^h^Calcuated from BIAsp30 BID change from baseline and subtracting the treatment difference

#### Hypoglycemia Rates {#Sec8}

Baseline values for severe and non-severe hypoglycemia were based on the UK Hypoglycaemia Study Group (UKHSG) observational study \[[@CR18]\]. The rates represent a better estimation of real-life rates compared with data from clinical trials, where a bias in patient selection and treatment setting occurs, resulting in potentially lower rates of hypoglycemia due to the exclusion of patients with recurrent severe hypoglycemia or hypoglycemic unawareness \[[@CR19]--[@CR25]\]. The T2DM group which used insulin for more than 5 years was perceived as being representative of the population who would consider using IDegAsp. The rates of hypoglycemia reported were 10.2 and 0.7 events per patient year of exposure (PYE) for non-severe and severe hypoglycemia, respectively \[[@CR18]\]. These estimates were taken as the base case for the comparator BIAsp 30 group (Table [1](#Tab1){ref-type="table"}b). To estimate the corresponding hypoglycemic event rates for IDegAsp, the relative rate ratio of hypoglycemia derived from the combined analysis was applied (Table [1](#Tab1){ref-type="table"}b). Hypoglycemic event rates were analyzed in mutually exclusive groups to avoid double counting of events: i.e., severe events, non-severe events occurring during the day (diurnal), and non-severe events occurring during the night (nocturnal). During the trials, hypoglycemia was classified as severe (requiring assistance from another person) or confirmed (PG measurement of \<3.1 mmol/L or severe). Nocturnal confirmed hypoglycemia included confirmed episodes with time of onset from 00:01 h to 05:59 h.

#### BMI {#Sec9}

In the combined analysis, there was less weight gain with IDegAsp versus BIAsp 30 \[[@CR9]\]. A post hoc analysis calculated the change in BMI from baseline for BIAsp 30. Using the estimated difference (IDegAsp−BIAsp30) derived from the combined analysis, the corresponding change from baseline in BMI for IDegAsp was calculated, adjusting for the covariates treatment, trial, anti-diabetic therapy at screening, sex, age, region, and baseline BMI (Table [1](#Tab1){ref-type="table"}c).

#### SMBG Testing {#Sec10}

The titration schedule recommended for use of SMBG tests with BIAsp 30 (six SMBG tests per week) was applied in the cost-effectiveness model \[[@CR26]\]. For IDegAsp, the once-weekly titration schedule for twice-daily administration was applied in the cost-effectiveness model (six SMBG tests per week) \[[@CR7], [@CR8]\].

### Cost Data {#Sec11}

All costs are calculated in Danish Kroner (DKK) (1 GBP = 9.4464 DKK,13 May 2016).

#### Cost of Insulin, Needles, and SMBG Tests {#Sec12}

The cost of insulin was based on prices published by the Danish Medicines Agency \[[@CR27]\] and the cost of needles, SMBG test strips, and lancets were based on prices published by the wholesaler Nomeco (Copenhagen, Denmark) \[[@CR28]\] (Table [2](#Tab2){ref-type="table"}).Table 2Unit costs for insulin, needles, and SMBG tests (Danish Kroner, DKK)ProductPrice per pack (excl. VAT)Units per packPrice per unit (excl. VAT)Insulin^a^Degludec/Aspart739.0815000.49NovoMix^®^367.2015000.24Needles^b^NovoFine^®^ 8 mm 30G192.001001.92SMBG tests^c^Test strip270.40505.41Lancet112.002000.56Unit cost, SMBG test----5.97*SMBG* self-measured blood glucose, *VAT* value-added tax^a^Danish Medicines Agency \[[@CR27]\]^b^It was assumed that the NovoFine^®^ needle was used with both insulin degludec/insulin aspart and biphasic insulin aspart, and a new needle was used for every injection, as per the recommendations. Lowest price on the wholesaler Nomeco's price \[[@CR28]\]^c^The cost of an SMBG test was calculated as the price of one test strip plus one lancet based on the lowest price of SMBG test strips and lancets on the wholesaler Nomeco's price list \[[@CR28]\]

#### Cost of Hypoglycemic Events {#Sec13}

The direct costs associated with a single hypoglycemic event represent the sum of the cost of treating the hypoglycemic event itself plus the costs of additional SMBG tests in the week following the event (Table [3](#Tab3){ref-type="table"}). The cost per event was multiplied by the annual rate of hypoglycemia to obtain an annual cost per insulin-treated patient.Table 3Total cost of an average severe/non-severe hypoglycemic event (Danish Kroner, DKK)Unit costUtilization per hypoglycemic eventSevereNon-severeQuantityCostQuantityCostGlucagon172.48^a^1.00^b^172.480.000Ambulance/on-site emergency team3408.71^c^0.25^d^862.400.000Hospital visit \>24 h22,117.00^e^0.05^d^1172.200.000Hospital visit ≤24 h504.00^f^0.23^d^116.930.000GP136.43^g^0.0000.05^k^6.82Hospital/diabetes clinic702.00^h^0.0000.04^k^28.08Other health-care professional26.71^i^0.0000.03^k^0.80SMBG tests5.97^j^2.15^k^12.832.15^k^12.83Total----2336.84--48.53*GP* general practitioner, *SMBG* self-measured blood glucose^a^Danish Medicines Agency \[[@CR27]\]^b^It was assumed that all patients experiencing a severe hypoglycemic event received glucagon^c^Dansk Sundhedsinstitut (DSI) \[[@CR45]\]; the unit cost was inflated to a 2016 price level applying the January 2016 consumer price index from Statistics Denmark \[[@CR46]\]^d^Based on clinical trial data \[[@CR29]\]^e^Hospitalization fee assumed (DRG 1013 charge) \[[@CR47]\]^f^Assumed to be a fee of an acute hospital service for ≤24 h (DAGS AA01C charge) \[[@CR48]\]^g^Assumed to be a GP visit fee (0101). Danish Medical Association fee \[[@CR49]\]^h^Assumed to be an ambulatory hospital visit (BG50A) \[[@CR48]\]^i^Assumed to be the cost of telephone consultation with a GP (0201). Danish Medical Association fee \[[@CR49]\]^j^The cost of an SMBG test was calculated as the price of one test strip plus one lancet based on the lowest price of SMBG test strips and lancets on the wholesaler Nomeco's price list \[[@CR28]\] (Table [2](#Tab2){ref-type="table"})^k^Based on clinical trial data from the combined analysis (a post hoc analysis)

The proportion of patients contacting a health-care professional (HCP) was obtained from the clinical trials, where patients completed a questionnaire regarding non-severe hypoglycemia events. To obtain information on the resource use associated with severe hypoglycemia, an analysis was conducted on all severe hypoglycemic events in the IDeg and IDegAsp clinical trial program. Of the 95 severe hypoglycemic events in patients with T2DM on multiple daily injection regimens, 25.3% required an ambulance or an on-site emergency team, 23.2% a hospital stay of ≤24 h, and 5.3% a hospital stay of \>24 h (Table [3](#Tab3){ref-type="table"}) \[[@CR29]\].

The use of extra SMBG tests in the week following a non-severe event was also based on a questionnaire from the clinical trials. A mean of 2.15 additional SMBG tests were used following a non-severe event in the combined analysis. This appears conservative compared with an observational study across four countries (USA, UK, Germany, and France) with an average of 5.6 additional SMBG tests per non-severe hypoglycemic event \[[@CR30]\], and a study that reported an increase of 3.7 SMBG tests per event in Denmark \[[@CR31]\]. It was conservatively assumed that this testing pattern was similar for severe events as the extra SMBG tests following hypoglycemic events were collected for the non-severe events only in the clinical trials.

### Utility Data {#Sec14}

The effects that were incorporated in the model were the disutility (reduction in quality of life) associated with hypoglycemia \[[@CR32]\], weight gain (measured as BMI) \[[@CR33]\], and frequency of SMBG testing \[[@CR34]\]. The multiplication of utilities and life years then provided QALYs.

#### Disutility per Hypoglycemic Event {#Sec15}

Published disutility values, obtained using the well-established time trade-off (TTO) methodology, were used. Utility values were obtained using a Web-based survey asking respondents hypothetical questions to elicit the health-related quality of life impact of living with various frequencies of hypoglycemic events \[[@CR32]\]. Disutility values were 0.057 for a severe event and 0.004 and 0.007 for non-severe daytime and non-severe nocturnal hypoglycemic events, respectively \[[@CR32]\]. There was a significant difference in disutility associated with non-severe daytime and non-severe nocturnal hypoglycemia \[[@CR32]\]. To investigate the incremental impact of IDegAsp, the disutility per hypoglycemic event was multiplied by the event rate per year. This was estimated separately for severe, non-severe daytime, and non-severe nocturnal hypoglycemic events.

#### Disutility of SMBG testing {#Sec16}

The disutility (pain and discomfort) associated with SMBG testing was also investigated using a TTO survey, giving a disutility per additional SMBG of 0.0000221 \[[@CR34]\], which was multiplied by the number of SMBG tests per year.

#### Disutility Associated with Higher BMI {#Sec17}

A multinational survey utilizing the EQ-5D questionnaire to measure the impact of diabetes complications, including BMI, calculated a disutility value of 0.0061 per BMI unit above 25 kg/m^2^ \[[@CR33]\].

Sensitivity Analyses {#Sec18}
--------------------

### One-Way Sensitivity Analyses {#Sec19}

To assess the robustness of these data and the impact of varying key assumptions and outcomes used in the base case on the cost-effectiveness results, several one-way sensitivity analyses were conducted (Table S1 in the supplementary material).

The base-case time horizon was 5 years, so the effects of time horizons of 1, 2, 3, and 10 years were investigated. Sensitivity analyses with discount rates of 0% and 5% were applied to investigate the effect of discounting.

Hypoglycemia event rates for Denmark from a recent multinational observational study were included as a sensitivity analysis, which reported severe, non-severe daytime, and nocturnal rates of 0.3, 13.6, and 8.3 events per PYE, respectively, for insulin-treated patients (classified as T2DM 'other' which included mixed insulins comparable to the present study) \[[@CR35], [@CR36]\].

The observed hypoglycemia clinical trial event rates per PYE from the combined analysis were also applied as a sensitivity analysis: 9.61 and 10.50 for non-severe daytime events during the titration and maintenance periods, respectively; 1.96 and 2.30 for non-severe nocturnal events during the titration and maintenance periods, respectively; and 0.13 and 0.23 for severe events during the titration and maintenance periods, respectively.

The costs of severe hypoglycemia were increased or decreased by 20% from the base case.

The estimated BMI difference (IDegAsp−BIAsp30) derived from the combined analysis was assumed to be zero in a sensitivity analysis.

Instead of the base-case TTO values \[[@CR32]\], disutility values of 0.0036 and 0.0118 per non-severe and severe hypoglycemic event, respectively, were obtained from a UK-based study of patients with diabetes \[[@CR37], [@CR38]\].

Clinical results from the IDegAsp global trial, which included European patients \[[@CR7]\], were used in a sensitivity analysis, as it could potentially be considered more representative for a Danish setting.

Instead of the SMBG disutility derived from the TTO study used for the base case, a disutility of zero associated with SMBG testing was assumed in a sensitivity analysis.

The disutility associated with BMI was assumed to be zero in a sensitivity analysis.

### Probabilistic Sensitivity Analysis {#Sec20}

A probabilistic sensitivity analysis (PSA) was conducted to capture the impact of statistical uncertainty accounting for the stochastic uncertainty in the input parameters used in the model. In a PSA, all stochastic input parameters can be varied simultaneously within a plausible range given statistical distributions for the input parameters in the model. Standard errors for the parameters were used and a log-normal distribution for rate ratios and normal distributions around continuous variables were used (Table S2 in the supplementary material). The PSA allows for an estimate of the certainty that a given intervention is cost-effective at different cost-effectiveness thresholds to be evaluated. The PSA were repeated with 10,000 iterations.

Compliance with Ethics Guidelines {#Sec21}
---------------------------------

This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.

Results {#Sec22}
=======

This analysis shows that IDegAsp is a cost-effective treatment option compared with BIAsp 30 in patients with T2DM. The estimated ICER in the base-case analysis was 81,507.91 DKK (Table [4](#Tab4){ref-type="table"}).Table 4Total costs and effects per patient for 5 years for IDegAsp versus BIAsp 30IDegAsp (DKK)BIAsp 30 (DKK)Incremental cost (DKK)Costs Pharmacy costs  Insulin60,565.7435,703.4224,862.32  Needles6616.016616.010  Routine SMBG tests8813.488813.480 Hypoglycemic event costs  Non-severe daytime events1501.381935.76--434.38  Non-severe nocturnal events157.54399.29--241.75  Severe events1655.937716.18--6060.25Total costs79,310.0861,184.1418,125.94Effects QALY3.53663.31420.2224 ICER (cost per QALY)----81,507.91*BIAsp 30* biphasic insulin aspart, *DKK* Danish Kroner, *ICER* incremental cost-effectiveness ratio, *IDegAsp* insulin degludec/insulin aspart, *QALY* quality-adjusted life year, *SMBG* self-measured blood glucose

The total incremental discounted cost per patient over 5 years of IDegAsp compared to BIAsp 30 treatment was 18,125.94 DKK, mainly due to an increased insulin cost (Table [4](#Tab4){ref-type="table"}). A lower incremental cost of treating non-severe and severe hypoglycemia was observed (Table [4](#Tab4){ref-type="table"}), due primarily to the statistically significant reduction in hypoglycemic events in the maintenance period with IDegAsp versus BIAsp 30 in the combined analysis (Table [1](#Tab1){ref-type="table"}).

One-Way Sensitivity Analyses {#Sec23}
----------------------------

In all sensitivity analyses, ICERs were below normally accepted thresholds, with estimates ranging from 71,012 DKK to 209,446 DKK per QALY gained (Table S1). Varying the time horizon had a small impact on the ICER, with a lower cost per QALY gained with a 10 year time horizon. Similarly, changing the discount rate did not have a significant impact on the ICER. The rate of hypoglycemia applied to the model had a larger impact on the results, with the higher published rates from Denmark \[[@CR35], [@CR36]\] resulting in a lower ICER (71,012 DKK) compared to the base case.

Using the observed hypoglycemia event rates from the combined analysis, where fewer severe hypoglycemic events were observed than in the UKHSG study, IDegAsp was cost-effective with an ICER of 153,440 DKK per QALY gained. When the cost of hypoglycemia was increased or decreased by 20%, IDegAsp was still cost-effective versus BIAsp 30, with ICERs of 76,049 DKK and 86,968 DKK, respectively. Using the disutilities per hypoglycemic event published by Currie et al. \[[@CR37]\] resulted in an ICER of 209,446 DKK. Using the clinical data from the global trial instead of the combined analysis resulted in an ICER of 100,289 DKK \[[@CR7]\]. Assuming a disutility per SMBG test of 0 did not have a significant impact on the ICER, compared with the base case.

Probabilistic Sensitivity Analysis {#Sec24}
----------------------------------

The PSA input variables are outlined in Table S2 in the supplementary material. At a willingness-to-pay threshold of 250,000 DKK per QALY gained, the probability that IDegAsp was cost-effective relative to BIAsp 30 was 99.5% (Fig. S1 in the supplementary material).

Discussion {#Sec25}
==========

Due to limited health-care resources, demonstrating the value of new therapies is an essential part of clinical and economical decision making. This simple and transparent short-term cost-effectiveness model, conducted from a Danish health-care perspective, focuses on the impact of important aspects of insulin therapy, including hypoglycemia and dosing. For patients with T2DM, IDegAsp is a cost-effective treatment compared with BIAsp 30, with an ICER of 81,507.91 DKK, over a 5-year time horizon. Several one-way sensitivity analyses and a PSA also found that IDegAsp was cost-effective versus BIAsp 30, supporting the robustness of the analysis. The ICERs were stable when the rates of hypoglycemia, unit cost of hypoglycemia, and the disutility of a hypoglycemic event were varied, ranging from 71,012 DKK to 209,446 DKK, all cost-effective based on a threshold of 250,000 DKK. In Denmark, there is no official published cost-effectiveness threshold. However, two recent Danish cost-effectiveness studies have applied thresholds varying from 250,000 to 500,000 DKK per QALY, with the one in the field of diabetes applying a threshold of 250,000 DKK \[[@CR39], [@CR40]\].

The two-trial combined analysis was used in the base-case model to increase the sample size and thereby strengthen the certainty of the parameter estimates derived from individual trials. Previously, a pre-specified hypoglycemia meta-analysis using pooled data from seven trials in the IDeg clinical program was conducted \[[@CR41]\]. The combined analysis used here was not pre-specified; however, it was conducted using the same methodology as the IDeg meta-analysis \[[@CR41]\] the hypoglycemia classification described in a second IDeg meta-analysis \[[@CR42]\].

The combined analysis showed that, at similar HbA~1c~ levels, IDegAsp resulted in lower rates of overall and nocturnal confirmed hypoglycemia, particularly during the maintenance period, and less weight gain compared with BIAsp 30, while using a lower dose \[[@CR9]\]. Although hypoglycemia is not a problem for all insulin-treated patients, its frequency tends to increase with longer disease duration and more intensive insulin regimens \[[@CR23]\]. Additionally, treatment of hypoglycemia is associated with considerable resource use and cost and is a burden to patients \[[@CR29], [@CR43], [@CR44]\]. In this analysis, the difference in the rates of hypoglycemia had a noticeable impact on the ICER. In this model, the mean population rates of hypoglycemia from published studies were used in the base case and sensitivity analysis \[[@CR18], [@CR35], [@CR36]\] to more closely reflect the rates observed in routine clinical practice versus clinical trials (where patients at high risk of severe hypoglycemia are excluded). The UKHSG rates used in the base-case analysis \[[@CR18]\] were a conservative estimate compared with the rates in a Danish population used for a sensitivity analysis, where the rates of non-severe daytime and nocturnal hypoglycemia were higher \[[@CR35], [@CR36]\]. Hypoglycemia disutilities from a global (US, UK, Germany, Sweden) TTO study were applied to the base-case model \[[@CR32]\] and those from a UK setting in a sensitivity analysis \[[@CR37]\]. Therefore, in subpopulations of patients, who experience recurrent hypoglycemia, hypoglycemia unawareness, or nocturnal hypoglycemia, a treatment such as IDegAsp might provide additional value for money as compared to the base case. The lower dose required for equivalent glycemic control for IDegAsp compared to BIAsp 30 in the combined analysis contributed to the cost-effectiveness of IDegAsp. The lower weight gain (measured by BMI) only had a limited impact on the cost-effectiveness results.

All modeling approaches are critically influenced by the quality of the input parameters. This model only used parameter estimates for which a statistically significant difference between the treatment arms was documented and assumed that all other differences were due to random variation. This cost-effectiveness model is limited by a variety of factors. The clinical data are derived from post hoc analyses of two clinical trials. The generalizability of clinical trials with high internal validity but usually low external validity, due to the highly selected population, which may not be representative of a real world clinical practice setting, is a common limitation inherent to economic modeling. The model assumed patients continued treatment with IDegAsp and BIAsp 30 for the 5-year period, without changing to another insulin regimen. As the data are based on treat-to-target clinical trials with no differences in HbA~1c~, any differences in mortality and morbidity are not expected and so not included in the model.

As with most models, the cost data for hypoglycemia were collected from a variety of publicly available sources, which measure parameters differently and may not accurately reflect the economic burden of hypoglycemia. The resources used following a hypoglycemia event were collected during the clinical trials for a selected population and may not represent the burden seen in clinical practice. The actual costs of hypoglycemia may be higher as the estimations did not take into consideration out-of-pocket expenses or lost work productivity. Finally, the model is based on comparable glycemic control between IDegAsp and BIAsp 30, with a potentially lower insulin dose requirement with IDegAsp. To address some of these limitations, more extensive clinical practice experience with IDegAsp would be useful for further health economic evaluations.

Conclusions {#Sec26}
===========

In conclusion, IDegAsp is a cost-effective alternative to BIAsp 30 for the treatment of T2DM in Denmark, based on the base case and sensitivity analyses with this short-term cost-effectiveness model.
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